RFWA
MRSN

RPg Family Wealth Advisory’s Mersana Therapeutics MRSN Stock Holding History

RPg Family Wealth Advisory’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$25.3K Sell
38
-36
-49% -$20K 0.01% 205
2020
Q3 		$34.5K Hold
74
– – 0.02% 182
2020
Q2 		$43.4K Sell
74
-31
-30% -$10.6K 0.03% 164
2020
Q1 		$15.4K Buy
+105
New +$18.3K 0.01% 214

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

RPg Family Wealth Advisory's MRSN Position: Q4 2020 in Review

RPg Family Wealth Advisory reduced its Mersana Therapeutics (MRSN) stake by 49% in Q4 2020, selling an estimated $20K and leaving 38 shares worth $25.3K. The position accounts for 0.01% of the portfolio, ranked #205.

RPg Family Wealth Advisory first reported a position in MRSN in Q1 2020 and has held it in 4 quarters since. The position peaked at $43.4K in Q2 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

  • RPg Family Wealth Advisory held 38 shares of Mersana Therapeutics worth $25.3K as of Q4 2020.
  • RPg Family Wealth Advisory sold 36 Mersana Therapeutics shares in Q4 2020, an estimated $20K.
  • Mersana Therapeutics made up 0.01% of RPg Family Wealth Advisory's portfolio in Q4 2020, its #205 holding.
  • RPg Family Wealth Advisory first reported a position in Mersana Therapeutics in Q1 2020 and has held it in 4 quarters since.
  • RPg Family Wealth Advisory's Mersana Therapeutics position peaked at $43.4K in Q2 2020.
  • 151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on RPg Family Wealth Advisory's 13F filing for Q4 2020, filed 16 Feb 2021.